COVID-19 Research Project
The aim of this research project is to understand the immune dysregulation in COVID-19 which is the primary cause of lung damage, leading to death, in order to change the course of the pandemic. The hypothesis is that autoimmunity to ACE-2 (the viral entry receptor) is triggered when elevated levels of serum ACE-2 bind to viral spike proteins. Research at Johns Hopkins University recently confirmed a part of this hypothesis by identifying IgM autoantibodies to ACE-2 in the serum of severe cases. This research project is expected to focus on a comprehensive search for autoantibodies to ACE-2 in people with COVID-19.
Dr Philip McMillan
Co-Founder & Executive Director
Medical doctor with a unique collaborative approach to medical research, applying the fundamentals of physiology and pathology to understand disease. Focused on COVID-19, long Covid and chronic health conditions such as dementia and arthritis.
Jacqueline Allison PhD CFA
Co-Founder
Investment and communications professional with more than twenty years of corporate and financial markets experience, and a passion for helping others. Director of several early-stage companies across multiple sectors including healthcare.
Collaboration with Vrais Héros Foundation
McMillan Research is collaborating with Vrais Héros Foundation to raise funds for medical research. Vrais Héros Foundation provides a community care programme in support of COVID-19 first responders. Its purpose is to support nurses in hospital emergency wards in a mindful way, with whole-person care packages during the COVID-19 pandemic, and potentially thereafter.
Disclaimer
McMillan Research does not currently have real world evidence data regarding all aspects of autoimmunity in COVID-19. The theory of autoimmunity in COVID-19 could form the basis for clinical investigation and medical monitoring. There are many challenges associated with clinical trials, especially clinical human trials. A clinical trial study requires a comprehensive development plan, and may use clinical biostatistics. A centre for clinical research focused on long COVID, could potentially provide much needed solutions.